

Enhanced Equity Income

Q3 2018 Commentary

Market Review:

US equities surged in the 3rd quarter of 2018, with the S&P 500 advancing 7.7% and the Russell 1000 Value up 5.7%. It was the strongest quarterly return for the S&P 500 since the 4th quarter of 2013. Health Care was the best performing sector, up 14.5%. The sector rallied on news that the Trump administration is considering drug pricing policies that would not significantly alter the current drug supply chain or pharmaceutical industry profits. Information Technology (+12.4%) continued to outperform and the Industrials sector rebounded (+10.0%) after being the worst-performing sector in the 2nd quarter; several leading transportation and capital goods firms posted strong earnings and the Purchasing Managers' Index rose in August to its highest level in 14 years. Energy (+0.6%) and Materials (+0.4%) were the laggards in the quarter. Energy stocks declined in July and August on concerns of rising supply and slowing global economic growth, and Materials stocks struggled partly on declining commodity prices.

Now a full decade from the financial crisis of 2008, the bull market that began in March 2009 is now the longest-running bull market in history. Stocks' ongoing advance has been supported by a host of positive economic data, including GDP growth for the 2nd quarter at 4.2%, unemployment at 3.9%, and consumer confidence at its highest level in 18 years. Moreover, year-over-year EPS growth for the S&P 500 is expected to be over 20% for 2018, the highest level of growth since 2010. However, the bull market will have to contend with a number of increasing headwinds going into 2019. The Federal Reserve, which increased interest rates another quarter percentage point in September, is expected to raise rates again in December and continue its tightening policy for the foreseeable future. Furthermore, while the US, Mexico and Canada reached a last minute compromise to revamp NAFTA, the Trump administration remains in conflict with China over trade disputes. After imposing 10% tariffs on an additional \$200B of Chinese imports, bringing the total to \$250B, China retaliated with tariffs on an additional \$60B of US imports on top of \$50B instituted earlier in the year. The trade war has raised concerns from business leaders about the potential disruption of supply chains and increase in materials costs.

Income and Options Summary:

Total income ended the quarter at 7.1% annualized; dividends contributed 3.5% and options 3.6%. In the quarter, 6 additional portfolio companies declared dividend increases with an average increase of 17.8%. Year-to date, 27 companies out of the 37 average have increased dividends at an average of 9.2%.

Options premiums remained attractive throughout the quarter, although market surges into the close of some monthly cycles increased the assignment rate to 42%, year-to-date. Calls were written against 16 positions in the portfolio during the month of September. Of the contracts written in the representative account year-to-date, 42% were assigned. Calls were written at an average of 2.3% out-of-the-money. The out-of-the-money average for calls written has been 2.3%, which is the average, long-term percentage.

Performance Analysis:

Growth outperformance within the broad market continued unabated during the quarter, as the Russell 1000 Growth Index outpaced its Value counterpart by 38% (9.17% versus 5.70%). However, the new highs made by the S&P 500 in late August were primarily due to market over-weightings in the five largest companies. Companies in the Information Technology and Consumer Discretionary sectors resumed their outperformance of the high-dividend sectors (Real Estate, Utilities, Consumer Staples, and Telecommunications).

The Enhanced Equity Income strategy recorded a very strong quarter, netting 6.60%, well in excess of its benchmarks; the S&P 500 Buy/Write Index (BXM) gained 4.92% and the SPDR Barclays High Yield Bond ETF (JNK) returned 2.47%. The strategy's allocations in the Communication Services, Real Estate, Consumer Staples and Energy sectors powered the return. They outgained those S&P sectors significantly, while trailing the Consumer Discretionary and Materials sectors.

Figure 1: Enhanced Equity Income Returns vs. Benchmark

	Q3	YTD	1 Yr	3 Yr	5 Yr	Since Incept*
SCCM Enhanced Equity Composite (gross)	6.9	2.9	4.2	11.2	8.2	9.7
SCCM Enhanced Equity Composite (net)	6.6	2.0	3.0	10.1	7.0	8.6
S&P 500 Buy-Write Index (BXM)	4.9	6.8	9.8	10.3	9.0	8.0
SPDR Barclays High Yield Bond ETF (JNK)	2.5	1.8	2.0	6.5	3.9	5.2

*December 31, 2010. Performance for periods greater than 1 year is annualized.

Portfolio Changes:

Buys

No positions were purchased during the quarter.

Sells

The position in **AstraZeneca (AZN)** was sold in the quarter. AstraZeneca has performed well over the past 18 months as three major oncology pipeline drugs approvals with differentiated trial results have bolstered the sales outlook for the company. However, at 22x 2018 earnings, the stock reflects improving top-line and pipeline prospects while earnings growth will be restrained by further patent expirations. While there will be several oncology pipeline trial results released in the next year, the competitive landscape in oncology has intensified and high drug costs in the space has drawn scrutiny from the US government and commercial payers. In addition, the company's increasing reliance on externalization – the monetization of specific pipeline drugs – has boosted earnings over the past several years but those deals have stripped the company of the full upside of success. The prospect of a takeout of the company appears to be less likely as US tax reform removed the need for tax inversions and Pfizer's past attempt to acquire AstraZeneca drew heavy scrutiny from UK authorities and UK shareholders. Lastly, Brexit poses an additional risk for AstraZeneca as it is a UK-domiciled company subject to the direct shockwaves of a potential hard Brexit outcome, namely weakness in the UK Pound and loss of market access. In terms of the dividend, AstraZeneca's gross yield is ~3.4%; however, the company appears unlikely to increase it given its high payout ratio and significant investment needs.

Thank you for your continued support. Feel free to reach out to us if you have any questions.

Respectfully,

James Cullen
Jennifer Chang, CFA
Timothy Cordle
Michael Kelly, CFA

Portfolio Managers, Schafer Cullen Capital Management, Inc.

Disclosure: Schafer Cullen Capital Management (SCCM or the "Adviser") is an independent investment advisor registered under the Investment Advisers Act of 1940. This information should not be used as the primary basis for any investment decision nor should it be considered as advice to meet your particular investment needs. The portfolio securities and sector weights may change at any time at the discretion of the Adviser. It should not be assumed that any security transactions, holdings or sectors discussed were or will be profitable, or that future recommendations or decisions will be profitable or equal the investment performance discussed herein. Investing in equity securities is speculative and involves substantial risk.

Past performance is no guarantee of future results. Market conditions can vary widely over time and can result in a loss of portfolio value. Individual account performance results will vary and will not match that of the composite or model. This variance depends on factors such as market conditions at the time of investment, and / or investment restrictions imposed by a client which may cause an account to either outperform or underperform the composite or model's performance. A list of all recommendations made by SCCM within the immediately preceding period of not less than one year is available upon request.

The strategy depicted in this report has been managed in accordance with the investment objectives of the strategy as determined by the Adviser. The Adviser has selected benchmarks, which in their opinion closely resemble the style of the securities held in the composite or model portfolio of the strategy (e.g. large cap value, small cap value, international, etc.). The securities held in the composite or model are actively managed while the benchmark index is not. Investors should be aware that the Adviser makes no attempt to match the portfolio securities, or the security weightings of the benchmark. The composite or model's performance will be affected greater by the price movements of individual securities as the composite or model is more concentrated, generally less than 100 securities, while a comparative benchmark will generally have between 500 and 2,500 securities where individual security price movements have a lesser affect. An individual cannot invest directly in an index.

In the case where this report displays model results, please be aware that such results do not represent actual trading and that results may not reflect the impact that material economic and market factors might have had on the Adviser's decision-making if the Adviser were actually managing clients' money.

Model and actual results reflect the deduction of advisory fees, brokerage or other commissions, and any other expenses that a client would have paid or actually paid (Net of Fee performance) and reflect the reinvestment of dividends and other earnings.

Schafer Cullen Capital Management, Inc. makes no representation that the use of this material can in and of itself be used to determine which securities to buy or sell, or when to buy or sell them; SCCM makes no representation, either directly or indirectly, that any graph, chart, formula or other device being offered herein will assist any person in making their own decisions as to which securities to buy, sell, or when to buy or sell them.

All opinions expressed constitute Schafer Cullen Capital Management's judgment as of the date of this report and are subject to change without notice.

Options are **not** suitable for all investors. Covered calls do not provide a guarantee of principal. Writing covered call options is considered to be a conservative strategy to boost the income return of a portfolio of stocks. Covered Call writing limits the upside profit potential of the underlying security. You will only gain the appreciation from your initial purchase price to the strike price plus the premium received from selling the call option and any dividends declared during the duration of the option. You give up any price gains above the strike price. Covered Calls have unlimited potential for downside loss. If the stock price goes down, the call option will expire worthless and you can keep the premium. However, the value of your stock portfolio can continue to decline. Options trading in general, involves high risk and you can lose a significant amount of money. Investing in options or any other financial instruments involves high risk and may not be suitable for everyone. Assignment on a written call is always possible. This strategy may incur higher costs relating to commissions charged for the execution of the covered calls. Unless the investor uses the strategy in a "wrap" or no-commission account, a high level of commission charges using this strategy may be incurred.

An investor holding shares with a low cost basis should consult his tax advisor about the tax ramifications of writing calls on such shares. SCCM does not provide tax advice and nothing in this document should be regarded as tax advice.